1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-07-03
48.24 CNY   +4.87%
06/27SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma and Amgen Announce Collaboration to Accelerate Two Innovative Medicines Benefitting Chinese Patients
PU
06/17SHANGHAI FOSUN PHARMACEUTICAL : Continuously Promoting Innovation and Internationalization Fosun Pharma Presents at 2022 BIO International Convention
PU
06/16SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. : Ex-dividend day for final dividend
FA
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/04/2022 Date
42.69 42.3 44.09 46 48.24 Last
37282350 30075870 68132250 76359140 64827270 Volume
-1.45% -0.91% +4.23% +4.33% +4.87% Change
Estimated financial data (e)
Sales 2022 44 046 M 6 574 M 6 574 M
Net income 2022 4 739 M 707 M 707 M
Net Debt 2022 16 490 M 2 461 M 2 461 M
P/E ratio 2022 24,9x
Yield 2022 1,09%
Sales 2023 49 556 M 7 396 M 7 396 M
Net income 2023 6 134 M 915 M 915 M
Net Debt 2023 13 772 M 2 055 M 2 055 M
P/E ratio 2023 20,2x
Yield 2023 1,38%
Capitalization 112 B 16 715 M 16 715 M
EV / Sales 2022 2,92x
EV / Sales 2023 2,54x
Nbr of Employees 36 279
Free-Float 59,3%
More Financials
Company
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical group organized around 4 areas of activities: - research, development and manufacturing of medicines (72.1% of net sales): for the treatment of cardiovascular diseases, digestive tract, metabolism, central nervous system and blood system disorders, and infectious diseases; - sale of medical equipments and diagnosis products (17.3%); - medical and... 
Sector
Pharmaceuticals
Calendar
08/30Earnings Release
More about the company
Ratings of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
06/27SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma and Amgen Announce Collaboration to Accelerat..
PU
06/17SHANGHAI FOSUN PHARMACEUTICAL : Continuously Promoting Innovation and Internationalization..
PU
06/16SHANGHAI FOSUN PHARMACEUTICAL (GROUP : Ex-dividend day for final dividend
FA
06/06SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - entering into sale and purchase a..
PU
06/02SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
06/01SHANGHAI FOSUN PHARMACEUTICAL : (1) re-appointment of chairman and vice chairman (2) appoi..
PU
06/01Shanghai Fosun Pharmaceutical Co., Ltd. Approves Final Dividend for the Year Ended 31 D..
CI
06/01Shanghai Fosun Pharmaceutical Co., Ltd. Announces Executive Appointments
CI
06/01Shanghai Fosun Pharmaceutical Co., Ltd. Announces Board Changes
CI
05/26Baidu-backed Pharmaceutical Platform YSB Files for Hong Kong IPO
MT
05/26Fosun Pharma Cleared to Start Phase II Study in China of Arteriovenous Malformation Tre..
MT
05/25SHANGHAI FOSUN PHARMACEUTICAL : Axicabtagene Ciloleucel - Fosun Kite's CAR-T Cell Therapy ..
PU
05/19SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma and VerImmune enter into an Exclusive License..
PU
05/19Shanghai Fosun Pharmaceutical Co., Ltd. Recommends Final Dividend for 2021, Dispatch of..
CI
05/13Fosun Pharma Unit Gets Nod to Start Phase II Study in China of Hematologic Disorder Tre..
MT
More news
News in other languages on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
06/01Shanghai Fosun Pharmaceutical (Group) Co., Ltd. approuve le dividende final pour l'exer..
06/01Shanghai Fosun Pharmaceutical (Group) Co., Ltd. annonce des nominations de cadres
06/01Shanghai Fosun Pharmaceutical (Group) Co., Ltd. annonce des changements au conseil d'ad..
05/26Fosun Pharma autorisé à lancer une étude de phase II en Chine sur le traitement de la m..
05/19Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Recommande le dividende final pour 2021..
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 48,24 CNY
Average target price 46,82 CNY
Spread / Average Target -2,95%
EPS Revisions
Managers and Directors
Yu Qing Chen Co-Chief Executive Officer
De Yong Wen Co-Chief Executive Officer
Dong Ming Li Co-President
Shirley Wu General Manager-Finance Management Department
Yi Fang Wu Co-Chairman